Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

With President Trump's on-off tariffs causing huge uncertainty in recent weeks, some value stocks have been getting even ...

Novo Nordisk (NVO) asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Doctors and patients have been hoping for a pill version that would be easier to take, in contrast to an injectable.

Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.